221 related articles for article (PubMed ID: 36058921)
1. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract][Full Text] [Related]
2. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.
Iwasaki S; Floor SN; Ingolia NT
Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A.
Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S
Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667
[TBL] [Abstract][Full Text] [Related]
4. Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action.
Zerio CJ; Cunningham TA; Tulino AS; Alimusa EA; Buckley TM; Moore KT; Dodson M; Wilson NC; Ambrose AJ; Shi T; Sivinski J; Essegian DJ; Zhang DD; Schürer SC; Schatz JH; Chapman E
J Med Chem; 2021 Nov; 64(21):15727-15746. PubMed ID: 34676755
[TBL] [Abstract][Full Text] [Related]
5. mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity.
Waldron JA; Tack DC; Ritchey LE; Gillen SL; Wilczynska A; Turro E; Bevilacqua PC; Assmann SM; Bushell M; Le Quesne J
Genome Biol; 2019 Dec; 20(1):300. PubMed ID: 31888698
[TBL] [Abstract][Full Text] [Related]
6. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
Iwasaki S; Iwasaki W; Takahashi M; Sakamoto A; Watanabe C; Shichino Y; Floor SN; Fujiwara K; Mito M; Dodo K; Sodeoka M; Imataka H; Honma T; Fukuzawa K; Ito T; Ingolia NT
Mol Cell; 2019 Feb; 73(4):738-748.e9. PubMed ID: 30595437
[TBL] [Abstract][Full Text] [Related]
7. eIF4B stimulates eIF4A ATPase and unwinding activities by direct interaction through its 7-repeats region.
Andreou AZ; Harms U; Klostermeier D
RNA Biol; 2017 Jan; 14(1):113-123. PubMed ID: 27858515
[TBL] [Abstract][Full Text] [Related]
8. A helicase-independent activity of eIF4A in promoting mRNA recruitment to the human ribosome.
Sokabe M; Fraser CS
Proc Natl Acad Sci U S A; 2017 Jun; 114(24):6304-6309. PubMed ID: 28559306
[TBL] [Abstract][Full Text] [Related]
9. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
10. Targeting the eIF4A RNA helicase as an anti-neoplastic approach.
Chu J; Pelletier J
Biochim Biophys Acta; 2015 Jul; 1849(7):781-91. PubMed ID: 25234619
[TBL] [Abstract][Full Text] [Related]
11. Functional mimicry revealed by the crystal structure of an eIF4A:RNA complex bound to the interfacial inhibitor, desmethyl pateamine A.
Naineni SK; Liang J; Hull K; Cencic R; Zhu M; Northcote P; Teesdale-Spittle P; Romo D; Nagar B; Pelletier J
Cell Chem Biol; 2021 Jun; 28(6):825-834.e6. PubMed ID: 33412110
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of hippuristanol-resistant mutants reveals eIF4A1 dependencies within mRNA 5' leader regions.
Steinberger J; Shen L; J Kiniry S; Naineni SK; Cencic R; Amiri M; Aboushawareb SAE; Chu J; Maïga RI; Yachnin BJ; Robert F; Sonenberg N; Baranov PV; Pelletier J
Nucleic Acids Res; 2020 Sep; 48(17):9521-9537. PubMed ID: 32766783
[TBL] [Abstract][Full Text] [Related]
13. Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.
Sridharan S; Robeson M; Bastihalli-Tukaramrao D; Howard CM; Subramaniyan B; Tilley AMC; Tiwari AK; Raman D
Front Oncol; 2019; 9():1311. PubMed ID: 31867270
[TBL] [Abstract][Full Text] [Related]
14. eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes.
Waldron JA; Raza F; Le Quesne J
Nucleic Acids Res; 2018 Apr; 46(6):3075-3087. PubMed ID: 29471358
[TBL] [Abstract][Full Text] [Related]
15. Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence.
Raza F; Waldron JA; Quesne JL
Biochem Soc Trans; 2015 Dec; 43(6):1227-33. PubMed ID: 26614665
[TBL] [Abstract][Full Text] [Related]
16. Programmed cell death 4 mechanism of action: The model to be updated?
Vikhreva PN; Kalinichenko SV; Korobko IV
Cell Cycle; 2017 Oct; 16(19):1761-1764. PubMed ID: 28853972
[TBL] [Abstract][Full Text] [Related]
17. Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation.
Marintchev A; Edmonds KA; Marintcheva B; Hendrickson E; Oberer M; Suzuki C; Herdy B; Sonenberg N; Wagner G
Cell; 2009 Feb; 136(3):447-60. PubMed ID: 19203580
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI.
Zakowicz H; Yang HS; Stark C; Wlodawer A; Laronde-Leblanc N; Colburn NH
RNA; 2005 Mar; 11(3):261-74. PubMed ID: 15661843
[TBL] [Abstract][Full Text] [Related]
19. Exploring the targeting spectrum of rocaglates among eIF4A homologs.
Naineni SK; Cencic R; Robert F; Brown LE; Haque M; Scott-Talib J; Sénéchal P; Schmeing TM; Porco JA; Pelletier J
RNA; 2023 Jun; 29(6):826-835. PubMed ID: 36882295
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.
Steinhardt JJ; Peroutka RJ; Mazan-Mamczarz K; Chen Q; Houng S; Robles C; Barth RN; DuBose J; Bruns B; Tesoriero R; Stein D; Fang R; Hanna N; Pasley J; Rodriguez C; Kligman MD; Bradley M; Rabin J; Shackelford S; Dai B; Landon AL; Scalea T; Livak F; Gartenhaus RB
Blood; 2014 Dec; 124(25):3758-67. PubMed ID: 25320244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
